Individuals who may warrant closer monitoring include: Those with a personal or family history of depression , anxiety, or other mood disorders People who have previously experienced mood changes on other weight-loss medications or GLP-1-based therapies Individuals with eating disorders or a complex relationship with food , for whom appetite suppression may have psychological implications (see NICE guideline NG69: Eating disorders: recognition and treatment) [10] Those experiencing significant life stressors alongside starting a new treatment People with poorly controlled type 2 diabetes , where fluctuating blood glucose levels both hypoglycaemia and hyperglycaemia can independently affect mood, concentration, and emotional wellbeing It is also worth acknowledging that obesity itself is associated with higher rates of depression and anxiety, and that the psychological experience of rapid body weight change whether positive or negative can be emotionally complex
In the United States, approximately 1 in 8 adults now use GLP-1 medications, making access and prescriber expertise increasingly important for safe, effective treatment
To defend its position in the anti-obesity market, Novo Nordisk has responded on multiple fronts, cutting prices on existing Wegovy doses in India by up to 37% in November 2025, partnering with Emcure to bring another semaglutide brand to the Indian market, and now moving to a higher-dose formulation that generics cannot replicate immediately
Personalized treatment plans
